Why the study?
Does a low threshold cTnT elevation (> 0.03 microg/l) predict increased risk of death or MI in patients with acute coronary syndromes?
Does a low threshold cTnT elevation (> 0.03 microg/l) predict increased risk of death or MI in patients with acute coronary syndromes?
A low threshold of cTnT elevation (> 0.03 microg/l) effectively risk-stratifies patients with acute coronary syndromes, predicting higher risks of MI and mortality.
Answers are grounded in this paper and cite their sources.
May support low-threshold cTnT for ACS risk stratification; leaves open impact on therapeutic decisions.
BACKGROUND: Cardiac troponins are the biochemical markers of choice for the evaluation of acute coronary syndromes (ACS). Using the first-generation test, most studies related adverse outcome to > 0.20 or 0.10 microg/l cardiac troponin T (cTnT) levels. With the highly sensitive and specific second- and third-generation assays, cTnT is undetectable in most healthy individuals. HYPOTHESIS: We evaluated whether a lower cTnT level, within 24 h of admission, could indicate an increased risk of future complications. METHODS: During 1998-1999, clinical data were collected in 260 patients with ACS. Cardiac troponin T was measured at arrival, and 4, 8, and 12-24 h thereafter. The maximum cTnT value was then used to assess, over a 15-month follow-up period, the cumulative risk of death or myocardial infarction (MI), as well as rates of events according to quartiles of cTnT values. RESULTS: Patients with < or = 0.03 microg/l cTnT levels had the lowest rate of adverse events and the best Kaplan-Meier event-free survival curve. Increasing cTnT levels were associated with stepwise increases in mortality rates and with a constant 10-fold increase in MI rates during follow-up. CONCLUSIONS: A low threshold cTnT elevation is recommended to assess the risk of ACS. All cTnT elevations > 0.03 microg/l predict a higher risk of MI during follow-up, whereas increasing values predict mortality in relation to the amount of elevation.
No takes yet. Share an insight, caveat, or question.
Solymoss et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: